(Press-News.org) February 20, 2026 (Washington, DC)—The Milken Institute Science Philanthropy Accelerator for Research and Collaboration (SPARC), in partnership with the Ann Theodore Foundation (ATF), has launched a new funding program to support a future clinical trial in cutaneous sarcoidosis. The program, ATF Sarcoidosis Inhibitor of mTOR (SIM), will award one two-year grant of up to US$575,000 to one or more independent biomedical researchers. The funding will support the awardee(s) in designing and conducting a Phase 2 investigator-initiated clinical trial that will assess whether a class of therapeutic called a mechanistic target of rapamycin (mTOR) inhibitor is effective in addressing cutaneous sarcoidosis.
ATF-SIM is the third sarcoidosis-related funding program that the Milken Institute and ATF have launched to support biomedical research focused on the condition. One of the partnership’s major aims is to reverse a historical precedent of sparse funding for sarcoidosis research. A debilitating and sometimes fatal inflammatory condition, sarcoidosis is marked by abnormal clusters of immune cells in various organs. The skin is the second-most affected organ after the lungs and is involved in approximately one-quarter of sarcoidosis cases. Sarcoidosis of the skin, or cutaneous sarcoidosis, may involve painful rashes, skin lesions, and subcutaneous growths.
The purpose behind ATF-SIM’s dedicated focus on evaluating a specific class of drug in a clinical trial is to validate the therapeutic’s recent, preliminary promise in sarcoidosis, which lacks disease-modifying treatments. Currently, the only US Food and Drug Administration-approved pharmaceuticals that are commonly used to treat sarcoidosis are general anti-inflammatory medications that may mitigate symptoms but cannot address the disorder’s underlying causes. However, a small 2024 clinical trial indicates that mTOR inhibitors, which target a specific sarcoidosis-related molecular pathway, may have a meaningful effect. Seven of the trial’s 10 participants with cutaneous sarcoidosis experienced sustained symptom improvement after completing treatment with the mTOR inhibitor sirolimus, a medication already approved for use in other inflammatory conditions.
“People living with sarcoidosis, which can be extremely painful and unpredictable, don’t currently have the treatment options they deserve,” said Melissa Stevens, executive vice president of strategic philanthropy at the Milken Institute. “In order to advance this potential treatment toward late-stage clinical trials and regulatory approval for use in cutaneous sarcoidosis, researchers must continue to show that an mTOR inhibitor has a significant effect in a new trial with more participants. We’re thrilled to work with ATF to ensure that the field accomplishes that next step as soon as possible.”
Since 2020, the Milken Institute and ATF have launched two other funding programs, ATF-LOMAS (Learning Opportunities in Medicine and Sarcoidosis) and ATF-BSI (Breakthrough Sarcoidosis Initiative), the latter of which has committed over $11 million to sarcoidosis research to date. They have also published a Giving Smarter Guide that identifies strategic opportunities for philanthropic investment in sarcoidosis.
“At ATF, we believe that we owe it to the sarcoidosis community to support promising research directions across all stages of development, including this timely opportunity to accelerate a potential treatment in the near term,” said Lisa Spalding, spokesperson for the Ann Theodore Foundation. “ATF-SIM augments—but does not supplant—our parallel efforts to support early-stage biomedical research and long-term scientific community-building through two other grant programs, which will reap benefits for decades to come. We must take every possible route to improving upon day-to-day symptom management in favor of long-term symptom relief.”
The funding program is now accepting applications through Monday, April 20, 2026, at 11:59 pm Eastern Time, and grant awardee(s) will be selected in June 2026. For more information, visit: https://milkeninstitute.org/content-hub/rfps/request-proposals-ann-theodore-foundation-sarcoidosis-inhibitor-mtor-sim-trial.
Media Contact
Libby Miller
limiller@milkeninstitute.org
About the Milken Institute
The Milken Institute is a nonprofit, nonpartisan think tank focused on accelerating measurable progress on the path to a meaningful life. With a focus on financial, physical, mental, and environmental health, we bring together the best ideas and innovative resourcing to develop blueprints for tackling some of our most critical global issues through the lens of what’s pressing now and what’s coming next.
Milken Institute Strategic Philanthropy tackles persistent societal challenges by guiding individuals and foundations with the insights and tools to develop strategies, implement giving programs, and foster collaboration to create a better, more equitable world.
The Milken Institute’s Science Philanthropy Accelerator for Research and Collaboration (SPARC) works to develop, launch, and lead initiatives that fund medical research and invest to accelerate the development of tools and treatments that will bring better health to millions of people. We partner with philanthropists, leading them through complex medical research and clinical systems.
About the Ann Theodore Foundation
The Ann Theodore Foundation is a grant-making private foundation that supports a broad range of initiatives, including opportunities for learning and enrichment for young people, food security, climate change mitigation, college access and success, and research towards a cure and improving care for people with sarcoidosis. The foundation's philanthropy is informed by the values of compassion, integrity, respect, and community.
END
Milken Institute, Ann Theodore Foundation launch new grant to support clinical trial for potential sarcoidosis treatment
2026-02-20
ELSE PRESS RELEASES FROM THIS DATE:
New strategies boost effectiveness of CAR-NK therapy against cancer
2026-02-20
Researchers at the Ribeirão Preto Blood Center and the Center for Cell-Based Therapy (CTC) conducted a study using the NK-92 cell line to test new models of chimeric antigen receptors (CARs) with specific costimulatory domains, such as 2B4 and DAP12. The tests showed that these components helped make the cells “ready to attack,” thereby increasing their ability to destroy tumors. The results were published in the journal Frontiers in Immunology.
The CTC is one of the Research, Innovation, and Dissemination Centers (RIDCs) ...
Study: Adolescent cannabis use linked to doubling risk of psychotic and bipolar disorders
2026-02-20
Oakland, CA — Adolescents who use cannabis could face a significantly higher risk of developing serious psychiatric disorders by young adulthood, according to a large new study published today in JAMA Health Forum. The longitudinal study followed 463,396 adolescents ages 13 to 17 through age 26 and found that past-year cannabis use during adolescence was associated with a significantly higher risk of incident psychotic (doubled), bipolar (doubled), depressive and anxiety disorders. The study was ...
Invisible harms: drug-related deaths spike after hurricanes and tropical storms
2026-02-20
Tropical cyclones, including hurricanes and tropical storms, are linked to increased rates of drug-related deaths up to three months after the storm passes—particularly in higher-income, White communities and among younger populations. The study of more than 30 years of data by researchers at Columbia University Mailman School of Public Health points to one overlooked health impact of climate change, which is leading to more active and severe storms.
The study is the first to quantify the association between tropical cyclone exposure and psychoactive drug–related deaths broadly and ...
Adolescent cannabis use and risk of psychotic, bipolar, depressive, and anxiety disorders
2026-02-20
About The Study: This cohort study found that adolescent cannabis use was associated with increased risk of incident psychiatric disorders, particularly psychotic and bipolar disorders. These results could inform the development of clinical and educational interventions for parents, adolescents, and clinicians, as well as protective policies to prevent or delay adolescent cannabis use in the context of expanding cannabis legalization.
Corresponding Author: To contact the corresponding author, Kelly C. Young-Wolff, PhD, MPH, email kelly.c.young-wolff@kp.org.
To access the embargoed study: ...
Anxiety, depression, and care barriers in adults with intellectual and developmental disabilities
2026-02-20
About The Study: In this cross-sectional study, U.S. adults with intellectual and developmental disabilities experienced substantially higher rates of mental health conditions, treatment use, and cost-related barriers compared with those without functional impairments. These findings highlight critical gaps for accessible, affordable, and disability-informed mental health services and policy reforms to address systemic inequities.
Corresponding Author: To contact the corresponding author, Dimitri Christakis, MD, MPH, email dchristakis@specialolympics.org.
To access the embargoed study: Visit our For The Media website at this ...
Study: Anxiety, gloom often accompany intellectual deficits
2026-02-20
Adults with intellectual and developmental disabilities, such as autism and Down syndrome, experience substantially higher rates of anxiety and depression than the general population of adults, researchers reported today in JAMA Network Open.
The study, based on data from 44,000 adults, provides the first national estimates of mental health symptom prevalence, healthcare treatment and access barriers facing this population.
"Our findings paint a distressing picture of the mental health and healthcare for people with these disabilities in the United States," ...
Massage Therapy Foundation awards $300,000 research grant to the University of Denver
2026-02-20
Evanston, Ill. – February 18, 2026 – The Massage Therapy Foundation (MTF) announces the award of a research grant to University of Denver, Denver, Colo. The grant will support a three-year study entitled, “Prenatal Massage: A Complementary Approach for Maternal Health and Mental Health,” led by Primary Investigator Galena Rhoades, PhD.
The study will be conducted through a partnership between the University of Denver and Thriving Families, a Denver-based nonprofit organization serving perinatal women and birthing people from under-resourced ...
Gastrointestinal toxicity linked to targeted cancer therapies in the United States
2026-02-20
“This review comprehensively examines the mechanisms, clinicopathological features, and management strategies of GI toxicity induced by TKIs, ADCs, and CAR-T therapies, emphasizing the diagnostic role of pathologists in identifying treatment-related injury patterns.”
BUFFALO, NY — February 20, 2026 — A new paper was published in Volume 13 of Oncoscience on February 6, 2026, titled “Gastrointestinal toxicity of targeted cancer therapies in the United States: Clinicopathologic patterns, FDA safety frameworks, and implications for national patient protection.”
First author Muhammad Moseeb Ali Hashim and co-corresponding author ...
Countdown to the Bial Award in Biomedicine 2025
2026-02-20
The winning work of the Bial Award in Biomedicine 2025, selected from 58 nominations across 18 countries, will be announced at the Award Ceremony on February 24, 2026, at 6 pm, in Porto, and will be held in a hybrid format, allowing everyone to watch online.
With the amount of 350,000 Euros, this award, promoted by the Bial Foundation, seeks to recognise a work published in the broad biomedical field within the last 10 years, the results of which are considered of exceptional quality and scientific relevance.
Chaired ...
Blood marker from dementia research could help track aging across the animal world
2026-02-20
The protein “neurofilament light chain” (NfL) – studied in humans in the context of neurodegenerative diseases and aging – is also detectable in the blood of numerous animals, and NfL levels increase with age in mice, cats, dogs, and horses. Experts from the DZNE and the Hertie Institute for Clinical Brain Research (HIH) at the University of Tübingen report these findings in the scientific journal “PLOS Biology”. In their view, this biomarker could help to assess the biological age of animals and estimate their life expectancy.
The protein NfL is an indicator of nerve damage. It is released when neurons undergo change ...